KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Research & Development (2016 - 2026)

Gsk has reported Research & Development over the past 18 years, most recently at -$2.3 billion for Q1 2026.

  • For Q1 2026, Research & Development fell 23.88% year-over-year to -$2.3 billion; the TTM value through Mar 2026 reached -$17.3 billion, down 24.99%, while the annual FY2025 figure was $10.0 billion, 21.83% up from the prior year.
  • Research & Development for Q1 2026 was -$2.3 billion at Gsk, up from -$10.0 billion in the prior quarter.
  • Over five years, Research & Development peaked at -$1.5 billion in Q1 2022 and troughed at -$10.0 billion in Q4 2025.
  • A 5-year average of -$3.3 billion and a median of -$1.9 billion in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: grew 18.74% in 2022 and later plummeted 44.83% in 2025.
  • Year by year, Research & Development stood at -$6.4 billion in 2022, then dropped by 19.99% to -$7.7 billion in 2023, then dropped by 6.37% to -$8.2 billion in 2024, then fell by 21.83% to -$10.0 billion in 2025, then surged by 77.21% to -$2.3 billion in 2026.
  • Business Quant data shows Research & Development for GSK at -$2.3 billion in Q1 2026, -$10.0 billion in Q4 2025, and -$2.3 billion in Q3 2025.